نتایج جستجو برای: androgen antagonist

تعداد نتایج: 82143  

Journal: :Proceedings of the National Academy of Sciences of the United States of America 1999
L Pederson M Kremer J Judd D Pascoe T C Spelsberg B L Riggs M J Oursler

For many years it has been recognized that sex steroids have profound effects on bone metabolism. The current perception is that estrogen decreases bone resorption and androgen increases bone deposition. To investigate the potential for androgens to directly modulate bone resorption, we have examined avian osteoclast and human and mouse osteoclast-like cells for androgen responsiveness. There w...

2015
Arianna Giacomini Sara Matarazzo Katiuscia Pagano Laura Ragona Sara Rezzola Michela Corsini Emanuela Di Salle Marco Presta Roberto Ronca

Fibroblast growth factor-8b (FGF8b) affects the epithelial/stromal compartments of steroid hormone-regulated tumors by exerting an autocrine activity on cancer cells and a paracrine pro-angiogenic function, thus contributing to tumor progression. The FGF8b/FGF receptor (FGFR) system may therefore represent a target for the treatment of steroid hormone-regulated tumors. The soluble pattern recog...

2018
Rachana Patel Janis Fleming Ernest Mui Carolyn Loveridge Peter Repiscak Arnaud Blomme Victoria Harle Mark Salji Imran Ahmad Katy Teo Freddie C Hamdy Ann Hedley Niels van den Broek Gillian Mackay Joanne Edwards Owen J Sansom Hing Y Leung

Metastatic castration-resistant prostate cancer (mCRPC) is a lethal form of treatment-resistant prostate cancer and poses significant therapeutic challenges. Deregulated receptor tyrosine kinase (RTK) signalling mediated by loss of tumour suppressor Sprouty2 (SPRY2) is associated with treatment resistance. Using pre-clinical human and murine mCRPC models, we show that SPRY2 deficiency leads to ...

2012
Mark Lazenby

J Adv Pract Oncol 2012;3:299–303 Androgen-deprivation therapy (ADT) is a common treatment for prostate cancer, as the androgen receptor (AR) plays a role in the development of this malignancy. Androgen-deprivation therapy agents can be classified as gonadotropin-releasing hormone (GnRH) agonists or GnRH antagonists. The most common GnRH agents in use are the GnRH agonists. However, these agents...

Journal: :Reproductive biology 2006
Marek Opałka Barbara Kamińska Helena Puchajda-Skowrońska Luiza Dusza

The mechanism of phytoestrogen action in gonadal cells of ganders has not been elucidated. The aim of the study was to investigate in Biłgoraj ganders the possibility of phytoestrogen action via estrogen or androgen receptors or via protein tyrosine kinase pathways in Leydig cells. Genistein and daidzein (5 and 50 microM) as well as equol (50 microM) inhibited testosterone (T) secretion by incu...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2011
Sayuri Takahashi Tomoyuki Watanabe Maiko Okada Kazuki Inoue Takashi Ueda Ichiro Takada Tetsuro Watabe Yoko Yamamoto Toru Fukuda Takashi Nakamura Chihiro Akimoto Tetsuya Fujimura Maiko Hoshino Yuuki Imai Daniel Metzger Kohei Miyazono Yasuhiro Minami Pierre Chambon Tadaichi Kitamura Takahiro Matsumoto Shigeaki Kato

Prostate cancer development is associated with hyperactive androgen signaling. However, the molecular link between androgen receptor (AR) function and humoral factors remains elusive. A prostate cancer mouse model was generated by selectively mutating the AR threonine 877 into alanine in prostatic epithelial cells through Cre-ERT2-mediated targeted somatic mutagenesis. Such AR point mutant mice...

2015
Qing Zhang Phillip J Gray

Prostate cancer remains a leading cause of cancer death in Europe and the United States and is an emerging problem in Asia despite significant improvements in available treatments over the last few decades. Androgen deprivation therapy (ADT) has been the core treatment of advance-staged disease since the discovery of prostate cancer's androgen dependence in 1941 by Huggins et al. [1] Options fo...

2014
Ziyang Yu Changmeng Cai Shuai Gao Nicholas I. Simon Howard C. Shen Steven P. Balk

Purpose: Galeterone inhibits the enzyme CYP17A1 and is currently in phase II clinical trials for castration-resistant prostate cancer (CRPC). Galeterone is also a direct androgen receptor (AR) antagonist andmay enhance ARdegradation. This studywas undertaken to determine themolecular basis for AR effects and their therapeutic potential. Experimental Design: Effects of galeterone on AR expressio...

Journal: :Cancer research 2004
Lei Zhang Gregory John Barritt

The Ca(2+)-permeable channel TRPM8 is thought to play an important role in the pathophysiology of prostate cancer. We have investigated the intracellular location of TRPM8 and its role as a Ca(2+)-permeable channel in an androgen-responsive and an androgen-insensitive prostate cancer cell line. We report evidence from immunofluorescence experiments that in the androgen-responsive LNCaP cell lin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید